Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Expectations By $0.03 EPS

Krystal Biotech (NASDAQ:KRYS) released its quarterly earnings data on Monday. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.03, Briefing.com reports. The firm had revenue of $70.28 million for the quarter, compared to analyst estimates of $65.27 million. During the same quarter in the previous year, the business posted ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis.

Krystal Biotech Trading Down 2.2 %

KRYS traded down $3.91 during trading hours on Wednesday, hitting $174.70. 337,535 shares of the company’s stock were exchanged, compared to its average volume of 381,679. The firm has a market cap of $4.99 billion, a P/E ratio of 95.51 and a beta of 0.84. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The firm has a 50 day moving average of $185.89 and a 200 day moving average of $164.54.

Analysts Set New Price Targets

Several analysts have recently weighed in on KRYS shares. Citigroup reissued a “neutral” rating and issued a $204.00 price target (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a research note on Monday. Stifel Nicolaus reissued a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, Chardan Capital upped their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average target price of $185.63.

Insider Buying and Selling at Krystal Biotech

In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).